Therapeutic Transdifferentiation: A Novel Approach for Ischemic Syndromes

Jennifer P. Connell, Santhisri Kodali, John P. Cooke

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The technological development of induced pluripotent stem cells (iPSCs) has overcome many of the limitations of adult and embryonic stem cells. We have found that activation of innate immunity signaling is necessary for this process, as it facilitates epigenetic plasticity in cells by a process called transflammation. More recently, we have discovered that transflammation also facilitates the transdifferentiation of cells directly from one somatic cell type to another. This insight may lead to a promising therapeutic pathway that avoids reverting cells all the way back to pluripotency before achieving a cell type of interest. While there is much therapeutic promise to transflammation and transdifferentiation, there is also evidence that transdifferentiation plays a role in some pathological conditions, including atherosclerosis. Ultimately, better understanding of transflammation will facilitate the development of regenerative therapies.

Original languageEnglish (US)
Pages (from-to)176-180
Number of pages5
JournalMethodist DeBakey cardiovascular journal
Issue number3
StatePublished - Jul 1 2015
Externally publishedYes


  • epigenetic plasticity
  • induced pluripotent stem cells
  • innate immunity
  • transdifferentiation
  • transflammation

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Therapeutic Transdifferentiation: A Novel Approach for Ischemic Syndromes'. Together they form a unique fingerprint.

Cite this